Hematopoietic cell transplantation (HCT) can be defined as the transfer of hematopoietic stem cells from one individual to another (allogeneic HCT) or the return of previously harvested cells to the same individual (autologous HCT) after manipulation of cells and/or the recipient. The goal of HCT is lifelong engraftment of administered cells, resulting in some or all of the recipient's lymphohematopoietic system being derived from the HCT graft. Full donor engraftment occurs when the recipient lymphohematopoietic system is fully replaced by progeny of the HCT graft. This is the ultimate goal of many HCT protocols, especially for achieving optimal graft vs tumor activity in patients with malignant disease. [8] [9] [10] However, in some clinical settings, a state of 'mixed chimerism', wherein elements of both the donor and recipient lymphohematopoietic system survive, may be sufficient to cure the underlying condition. 11, 12 Allogeneic HCT can cure or improve outcome in a wide variety of diseases, including leukemia, lymphoma, myeloproliferative disorders, myelodysplasia, BM failure syndromes, congenital immunodeficiencies, enzyme deficiencies and hemoglobinopathies. [13] [14] [15] [16] [17] However, because allogeneic HCT is associated with significant morbidity and mortality due to regimen-related toxicity, 18 infection 19 and GVHD, 20 a recommendation regarding transplantation for the individual patient requires careful risk assessment that takes into account disease status, 21 comorbidities, previous therapies, other standard therapies available for the underlying disease, 22 donor stem cell source 23 and histoincompatibility. 24 Autologous HCT can improve outcomes in neoplastic diseases 25 and autoimmune conditions, 26 and continues to be investigated as a platform for gene therapy. 27 Regimen-related toxicity and infections contribute to the morbidity and mortality associated with autologous HCT; however, morbidity due to GVHD generally does not occur after this procedure.
Substantial progress has been made in allogeneic HCT during the past 15 years as a result of improvements in four distinct, but interrelated, areas. First, improvements in the supportive care of patients with severe immunosuppression and myelosuppression have diminished morbidity and mortality due to infection. 19, 28, 29 Second, the critical contribution of immune-mediated graft vs tumor effects toward eradicating malignant disease and facilitating engraftment is now well established and factors prominently in the design of individual HCT regimens. 21 Third, alternative donor (nonsibling) transplants and new stem cell sources now provide HCT options for a larger percentage of potential candidates. 23, 30, 31 Fourth, newer, less toxic preparative regimens have been developed that allow reliable engraftment with a lower risk for transplantrelated mortality and long-term adverse effects. 18, 32 Classically, transfer of the hematopoietic cell graft was seen as a means of rescuing the recipient's lymphohematopoietic system from an otherwise lethal myeloablative preparative regimen. In this model, the preparative regimen was used as the primary tool to eradicate malignant disease or to eradicate the recipient's immune system when HCT was used to treat benign diseases. However, careful clinical studies over the last four decades have revealed that the effectiveness of allogeneic HCT in eradicating malignant disease is intimately linked to the activity of immunoreactive cells in the graft, most notably T cells and, in some cases, natural killer (NK) cells. 24, 33, 34 An indirect demonstration of this GVL effect comes from reports of increased leukemic relapse after syngeneic (identical twin) HCT and increased leukemia relapse after T-cell-depleted HCT. A direct demonstration has been provided by the ability of donor lymphocyte infusions to induce remission in a substantial number of patients with chronic myeloid leukemia. 35 Evidence for a graft vs tumor effect also exists for other malignancies, 36 but the effect seems to be less potent than that observed in chronic myeloid leukemia. Furthermore, even when HCT is performed for benign diseases, the rate and degree of donor engraftment can be enhanced with the use of donor leukocyte infusions, showing that immune cells also contribute to the engraftment process. Thus, HCT has evolved from a therapy designed primarily to provide lymphohematopoietic rescue after myeloablative conditioning to a form of immunotherapy, wherein mature immune cells contained within the graft and/or reconstituted from donor progenitors have an active role in eradicating the underlying neoplastic disease and in facilitating donor engraftment.
Expansion of graft sources has contributed to substantial progress in allogeneic HCT. Traditionally, allogeneic HCT involved the transfer of marrow grafts harvested from HLA-matched sibling donors, in which case histoincompatibility was limited to minor Ags for which reliable typing is not routinely available. Approximately 25-30% of potential HCT recipients will have a matched sibling donor available. Through the efforts of the National Marrow Donor Program in the United States and donor registries throughout the world, B12 million individuals have undergone preliminary HLA typing over the past 20 years, and, as a result, 75% of Caucasian individuals will find a suitably matched unrelated donor. However, for other racial or ethnic groups, the chance of finding a suitable donor using existent registries is substantially less. Recent studies have shown that with proper HLA matching, outcomes after matched unrelated donor HCT approach those reported for matched sibling transplants. Umbilical cord blood transplants have also shown promise. The benefits of umbilical cord blood as a stem cell source are ready accessibility and the ability to cross HLA barriers. 23, 31, 37, 38 Mismatched, related and haploidentical donor grafts also continue to have a role in clinical HCT, especially for patients with congenital immunodeficiency 39 and in specialized centers where this approach continues to be optimized. 40, 41 Beyond the multitude of choices regarding donor source, progress during the last 15 years has also shown that G-CSF-mobilized PBSC allografts provide a reliable source for engraftment, and offer the advantage of improved myeloid and T-cell recovery 30, 42 than that with traditional marrow grafts and thus fewer infections. However, G-CSF-mobilized blood grafts also seem to carry a greater risk for chronic GVHD as compared with marrow grafts. 23, 43, 44 New approaches have been developed to minimize the likelihood of graft failure, conditioning toxicity, GVHD and infections. [45] [46] [47] [48] The addition of T-cell-depleting agents (for example, antithymocyte globulin or alemtuzumab) to conditioning regimens has been associated with a reduced incidence of GVHD and diminished graft rejection but may delay immune recovery. Nonmyeloablative preparative regimens that use cytotoxic drugs or low-dose TBI in conditioning regimens have been associated with reduced nonrelapse mortality and have provided new options for HCT among the elderly and in patients with substantial comorbidities. The choice of preparative regimen and the decision regarding the relative merit of a myeloablative vs nonmyeloablative regimen are complex and should involve a risk-adapted strategy that takes into account the underlying disease, patient age, comorbidities, stem cell source, histoincompatibility and other relevant factors.
In summary, HCT has a central role in the treatment of a variety of benign and malignant diseases and the field continues to evolve rapidly, with new options for donor sources and preparative regimens. At the same time, standard treatments for many of the diseases in which HCT historically provided the mainstay of therapy have also evolved, rendering the decision of whether, when and how to proceed to HCT highly complex and requiring a careful consideration of the individual case, in light of evidence-based data. For patients who undergo HCT, the major causes of early morbidity and mortality are disease relapse, acute GVHD, infection, regimen-related toxicity and graft failure. Long-term survivors of HCT are at risk for a variety of long-term adverse effects, including chronic GVHD, infections, hypothyroidism, sterility, growth failure and other endocrine disturbances, cataracts, avascular necrosis, disease relapse and second malignancy. The incidence of each of those adverse effects varies greatly with differing preparative regimens, comorbidities, age at transplantation and whether the individual experiences chronic GVHD.
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Immune system recovery after HCT After myeloablative conditioning, HCT recipients typically experience a period of profound pancytopenia spanning days to weeks depending on the donor source. The rapidity of neutrophil recovery varies with the type of graft: approximate recovery time is 2 weeks with G-CSFmobilized peripheral blood grafts, 3 weeks with marrow grafts and 4 weeks with umbilical cord blood grafts. Neutrophil, monocyte and NK-cell recovery is followed by plt and red cell recovery, which is followed by B-and T-cell recovery ( Figure 1 ). Simultaneously, myeloablative regimens damage mucosal surfaces and thereby provide a source for bloodstream seeding of commensal pathogens that inhabit the gastrointestinal tract. As a result, infectious complications in the immediate post transplant period usually present as febrile neutropenia, with the severity of risk related to the depth and duration of neutropenia and the degree of mucosal damage induced.
Recipients of nonmyeloablative allogeneic transplants exhibit substantial heterogeneity in the depth and duration of pancytopenia, with some regimens accomplishing reliable engraftment without clinically significant myelosuppression. In regimens with minimal myelosuppression and minimal mucosal toxicity, the risk for infection in the immediate post transplant period is reduced. In fact, regimens based on low-dose TBI and fludarabine can sometimes be performed in the outpatient setting, with a virtual elimination of neutropenic complications.
Although the degree of myelosuppression is milder after nonmyeloablative regimens, the depth and extent of lymphodepletion tend to be similar, with prolonged periods of immune incompetence observed in recipients of both myeloablative and nonmyeloablative regimens. This is because engraftment of allogeneic hematopoietic progenitor cells requires significant recipient immunosuppression to prevent graft rejection, even in the context of full HLA matching. With some regimens, an essentially complete eradication of recipient lymphocytes is accomplished by the preparative regimen itself. However, with other regimens, depletion of recipient lymphocytes occurs more gradually by the use of donor leukocyte infusions after transplant. In both cases, the vast majority of HCT recipients experience near-total lymphocyte depletion, and thus must undergo lymphoid reconstitution through mature lymphocytes and lymphoid progenitors contained in the graft. Furthermore, except when T-cell-depleted HCT grafts are administered, all allogeneic HCT recipients must also receive some form of immunosuppression to prevent GVHD, further limiting immune competence.
Unlike the recovery of other hematopoietic lineages, which typically occur over the course of weeks after HCT, lymphocyte recovery is a prolonged process. Reestablishment of immunocompetence requires at least several months, and some patients continue to show immune deficits for several years after HCT. In general, NK-cells are the first lymphocyte subset to recover, followed by CD8 þ T cells, which often reach supranormal levels within 2-8 months after HCT. Subsequently, B cells and ultimately CD4 þ T cells recover. The pace and extent of recovery of each lymphocyte subset are highly dependent on several factors, which ultimately determine the degree, extent and duration of immune incompetence experienced by the individual HCT recipient (Figure 1) .
Regeneration of lymphocytes in humans is an inefficient process, which primarily involves two distinct pathways. In the first pathway, lymphocytes regenerate from BM lymphoid progenitors, thus recapitulating ontogeny and regenerating a naive immune system, similar to that found in a newborn child.
50 NK-cell recovery uses this pathway exclusively. Full recovery of NK-cell counts is typically achieved within 1-2 months after HCT. B cells are also primarily regenerated from lymphoid progenitor cells, as evidenced by the appearance of primitive B-cell subsets as the harbinger of B-cell immune reconstitution. 51 However, unlike NK-cell recovery, B-cell lymphopoiesis is highly dependent on a specialized marrow microenvironment termed the 'bursal equivalent', which is susceptible to damage by the preparative regimen and is exquisitely sensitive to the toxic effects of GVHD and/or its treatment. Indeed, patients who experience even a limited episode of steroid-responsive GVHD show significantly diminished B-cell reconstitution in the long term, compared with patients who do not experience GVHD. 52 Although recent data have shown that mature B cells can also contribute to B-cell reconstitution through homeostatic expansion, this pathway seems to be minor compared with the marrowderived pathway for B-cell regeneration.
Restoration of full humoral immune competence after HCT requires the reconstitution not only of naı¨ve B cells but also of a memory B-cell pool. The latter occurs as a result of environmental or vaccine-based exposure to common pathogens and also requires help from CD4 þ T cells. Therefore, even HCT recipients who do not experience GVHD and who show recovery of total B-cell numbers within 6 months post transplant should not be considered to have regained full humoral immunocompetence by this time. For at least 1 year after transplantation, essentially all HCT recipients remain predisposed to infections from encapsulated bacteria and viruses, against which neutralizing Abs provide a first line of defense. Serum IgG levels provide little insight into B-cell reconstitution, as long-lived, radioresistant plasma cells survive many preparative regimens 53 and can produce substantial circulating IgG without providing humoral responses to specific pathogens. The only reliable means by which one can assess humoral immune competence after transplantation is by documenting clinically significant rises in Agspecific Abs after vaccination or infection. Indeed, some medical centers use a rise in Ab levels in response to administration of a killed vaccine as a prerequisite for the use of live-attenuated vaccines.
Regeneration of T-cell is predominantly driven by a thymic-independent pathway, termed homeostatic peripheral expansion. Here, mature T cells contained within the graft dramatically expand in vivo in response to T-cell lymphopenia. This process is driven by a combination of factors, among which are increased availability of homeostatic cytokines, including IL-7 and IL-15, which accumulate during lymphopenia; inflammatory cytokines associated with tissue damage induced by the preparative regimen; and exposure to viral Ags (either environmentally or through reactivation) during the period of profound Of all the factors analyzed thus far, CD4 þ counts may provide the most readily available and predictive marker for the restoration of immune competence after HCT. Although the predictive value of low CD4 þ counts has not been as extensively studied in recipients of HCT as they have in HIV infection, several studies have shown that CD4 þ recovery is associated with diminished risk of infection and improved transplant outcomes.
56-59 When T-cell regeneration occurs through the ontogenic or thymicdependent pathway, there is a substantial rise in CD4 þ T-cell numbers, with recovery of naive CD4 þ and CD8 þ T cells and diversification of the T-cell repertoire.
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However, because the microenvironment of the thymus is highly susceptible to damage from age, therapy and GVHD, many adult HCT recipients show little or no thymic-dependent T-cell regeneration for months to years after HCT.
61-63 A study of adult recipients of autologous HCT for breast cancer revealed that with each advancing decade of patient age between 30 and 60 years, a decreasing percentage of patients achieved effective CD4 þ immune reconstitution after 2 years of follow-up.
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Beyond the general rule that all HCT recipients experience profound immunosuppression at some point, the degree of immunosuppression experienced by individual patients varies greatly and is influenced by several factors. First and foremost is the profound adverse effect of GVHD on the overall process. In essentially every series, GVHD severity correlates with the degree of immunosuppression and infectious complications. This correlation is due to a variety of factors that compound one another, including damage to lymphoid microenvironments, adverse effects of GVHD on homeostatic peripheral expansion, as well as the obvious impact that chronic immunosuppression has on a reconstituting immune system. Second, recipient factors such as age, comorbidities and infectious exposure before transplant contribute substantially to the risk of post transplant infectious complications. This is illustrated in studies of SCID patients, wherein outcomes are most successful in children who undergo transplantation before experiencing severe, life-threatening infection. 65 Third, graft-associated factors also have an important role. Recent studies have suggested that PBSC graft recipients show more rapid immune reconstitution, as measured by lymphocyte subsets, 42 whereas umbilical cord blood transplantation in adults 66, 67 and transplantation of profoundly T-cell-depleted haploidentical grafts result in poor immune reconstitution and high rates of infectious complications. The CD34 dose is crucial, and levels of 3 Â 10 6 CD34 þ cells per kg or more are associated with an improved hematopoietic recovery, a decreased incidence of fungal infections and improved overall survival in recipients of unmanipulated BMTs from HLA-identical sibling donors.
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Models that distinguish between infectious complications occurring during different post transplantation phases have been put forth, based largely on a myeloablative paradigm. Such a model is shown in Figure 2 , in which phase I is the preengraftment phase (o15-45 days after HCT); phase II is the post-engraftment phase (30-100 days after HCT); and phase III is the late phase (4100 days after HCT). During phase I, prolonged neutropenia and breaks in the mucocutaneous barrier result in substantial risk for bacteremia and fungal infections involving Candida species and, as neutropenia continues, Aspergillus species. In addition, HSV reactivation occurs during this phase. During phase II, infections relate primarily to impaired cell-mediated immunity. The scope and impact of this defect is determined by the extent of GVHD and the immunosuppressive therapy for it. Herpesviruses, particularly CMV, are common infectious agents during this period. Other dominant pathogens during this phase include Pneumocystis jiroveci and Aspergillus species. During phase III, persons with chronic GVHD and recipients of alternate-donor allogeneic transplants remain most at risk for infection. Common pathogens include CMV, VZV and infections with encapsulated bacteria (for example, Streptococcus pneumoniae). The relative risk for these infections is approximately proportional to the severity of the patient's GVHD during phases II and III. For recipients of nonmyeloablative grafts, substantial differences may be observed during phase I, but the susceptibility to infections during phases II and III is largely similar, and driven primarily by the status of the underlying disease, a history of GVHD and/or the need for ongoing immunosuppression. The risk of disease from community-acquired respiratory viruses is elevated during all three phases; however, in phase III, the outpatient status of HCT recipients can complicate efforts to reduce exposure and provide timely intervention.
Thus, the risk of infection is primarily determined by the time from transplant and the presence or absence of GVHD. Other factors include donor/host histocompatibility, disease status, graft type, graft contents, conditioning intensity and neutrophil engraftment (Table 3) . 6, 7, 52, [69] [70] [71] [72] [73] [74] Unfortunately, there is currently no definitive laboratory marker of immune reconstitution that can predict infectious risk that could be used to tailor infection prophylaxis. It is likely that the degree of immune recovery measured by various assays is associated with clinical outcomes, including infection rates, on the basis of retrospective studies that included relatively small numbers of patients (Table 4) . However, a rigorous proof of the association is lacking. Moreover, most of the published studies have focused on the association of immune assay results with outcomes that can be clearly defined and captured (for example, survival or nonrelapse mortality) rather than with infections. In addition, information from published studies is limited because of publication bias (that is, there is a tendency to publish studies that find an association rather than negative studies). Tools are now available to precisely monitor viral-specific (EBV, CMV) immune responses (HLA tetramers, IFN-g production assays) and may help in understanding this issue.
75 Large (ideally, prospective) studies are needed, first to conclusively determine which immune monitoring test has prognostic value and ultimately to determine whether outcomes would improve if such a test were used to tailor infection prophylaxis.
In summary, HCT is characterized by a variable period of early infectious complications caused largely by neutropenia and mucosal damage due to the preparative regimen, and such complications are readily predictable on the basis of clinical findings of mucositis and ANC. In addition, essentially all HCT recipients experience a prolonged period of immunosuppression characterized by profound defects in cell-mediated and humoral immunity. Unfortunately, there are no readily available surrogate markers to accurately measure the relative risk for individual patients. Consequently, these patients must be monitored carefully and receive early intervention for signs or symptoms of an infectious disease. In most patients, immunocompetence improves progressively with increasing time after transplant, an observation that has led to the current recommendations for revaccination at 6-24 months, including with some live vaccines at B24 months for patients who no longer receive immunosuppression and Guidelines for preventing infections in HCT C Mackall et al show no signs of GVHD. However, it is important to realize that many HCT recipients remain immunocompromized far beyond 2 years after transplant-especially individuals with chronic GVHD, for whom infection remains the most important cause of morbidity and mortality. Future work is needed to augment the degree of immune reconstitution toward pathogens and malignancy, and to identify accurate surrogate markers of immunocompetence to guide the long-term management of this high-risk population. 
